The inhibition of VEGFR and PDGFβ receptor (PDGFRβ) signaling to simultaneously target both endothelial cells and pericytes, respectively, has been investigated to enhance the efficacy of antiangiogenic tumor therapy and overcome the development of drug resistance in tumors. Here, PDGFRB is linked to neoplasm.